Expression of Notch pathway components (Numb, Itch, and Siah-1) in colorectal tumors: A clinicopathological study

Table 5 Correlations between expression levels of Notch, Numb, Itch, and Siah-1 and clinicopathological parameters in colorectal carcinoma

Levels	n	Notch			Numb		Itch			Siah-1
Parameters		(-)	(↓)	(↑)	(↓)	(↑)	(-)	(↓)	(↑)	(-)	(↓)	(↑)
		12	16	22	26	24	16	19	15	10	27	13
Age
64 ± 12.353 ≥	22	7 (31.8)	4 (18.2)	11 (50)	12 (54.5)	10 (45.5)	7 (31.8)	6 (27.3)	9 (40.9)	4 (18.2)	13 (59.1)	5 (22.7)
64 ± 12.353 <	28	5 (17.9)	12 ( 42 .9)	11 (39.3)	14 (50)	14 (50)	5 (17.9)	12 (42.9)	11(39.3)	6 (21.4)	14 (50)	8 (28.6)
Gender
Female	17	3 (17.6)	5 ( 29.5)	9 (52.9)	17 (51.5)	16 (48.5)	6 (35.3)	7 (41.2)	4 (23.4)	3 (17.6)	10 (58.8)	4 (23.5)
Male	33	9 (27.3)	11 (33.3)	13 (39.4)	9 (52.9)	8 (47.1)	6 (18.2)	11 (33.3)	16 (48.5)	7 (21.2)	17 (51.5	9 (27.3)
Localisation
Caecum	8	1 (12.5)	3 (37.5)	4 (50)	4 (50)	4(50)	0	3 (37.5)	5 (62.5)	2 (25)	4 (50)	2 (25)
Colon	16	3 (18.8)	3 (18.8)	10 (62.5)	9 (56.2)	7 (43.8)	5 (31.2)	5 (31.2)	6 (37.5)	3 (18.8)	9 (56.2)	4 (25)
Sigmoid	16	7 (43.8)	7 (43.8)	2 (12.5)	6 (60)	4 (40)	3 (30)	3 (30)	4 (40)	2 (12.5)	10 (62.5)	4 (25)
Rectum	10	1 (10)	3 (30)	6 (60)	7 (43.8)	9 (56.2)	4 (25)	7 (43.8)	5 (31.2)	3 (30)	4 (40)	3 (30)
Differentiationa
WD MD	24 13	6 (25) 4 (30.7)	13 (54.1) 2 (15.3)	5 (20.9) 7 (54)	8 (33.3) 8 (61.5)	16 (66.7) 5 (38.5)	5 (20.8) 3 (23.1)	5 (20.8) 5 (38.5)	14 (58.3) 5 (38.5)	7 (29.2) 2 (15.49	7 (29.2) 10 (76.9)	10 (41.7) 1 (7.7)
PD	13	2 (15.4)	1 (7.7)	10 (76.9)	10 (76.9)	3 (23.1)	4 (30.8)	8 (61.5)	1 (7.7)	1 ( 7.7)	10 (76.9)	2 (15.4)
Invasion
T1	7	1 (14.3)	1 (14.3)	5 (71.4)	1 (14.3)	6 (85.7)	2 (20)	0	5 (71.4)	2 (28.6)	3 (42.9)	2 (28.6)
T2	10	3 (30)	3 (30)	4 (40)	6 (60)	4 (40)	2 (20)	(30)	5 (50)	1 (10)	5 (50)	4 (40)
T3	23	6 (26.1)	7 (30.4)	10 (43.5)	15 (65.2)	8 (34.8)	5 (21.7)	11 (47.8)	7 (30.4)	5 (21.7)	5 (50)	4 (17.4)
T4	10	2 (20)	5 (50)	3 (30)	4 (40)	6 (60)	24 (30)	18 (36)	20 (40)	2 (20)	5 (50)	3 (30)
LNMa
Absent	19	3 (15.8)	13 (68.4)	3 (15.8)	6 (31.6)	13 (68.4)	5 (26.3)	2 (10.5)	12 (63.2)	6 (31.6)	5 (26.3)	8 (42.1)
Present	31	9 (29)	3 (9.7)	19 (61.3)	20 (64.5)	11 (35.5)	7 (22.6)	16 (88.9)	8 (25.8)	4 (12.9)	22 (71)	5 (16.1)
Lymphatic invasion
Absent	37	11(29.7)	13 (35.1)	13 (35.1)	20 (54.1)	17 (45.9)	7(18.9)	13 (35.1)	17 (45.9)	7 (18.9)	24 (64.9)	6 (16.2)
Present	13	1 (7.7)	3 (23.1)	9 (69.2)	6 (46.2)	7 (53.8)	5 (38.5)	5 (38.5)	3 (23.1)	3 (23.1)	3 (23.1)	7 (53.8)
Vascular invasion
Absent	42	12(28.6)	14(33.3)	16 (38.1)	23 (54.8)	19 ( 45.2)	8 (19)	16 (38.1)	18 (42.9)	8 (19)	25 (59.5)	9 (21.4)
Present	8	0	2 (25)	6 (75)	3 (37.5)	5 (62.5)	4 (50)	2 (25)	2 (25)	2 (25)	2 (25)	4 (50)
Perineural invasion
Absent present	31	6 (19.4)	12 (38.7)	13 (41.9)	15 (48.4)	16 (51.6)	8 (25.8)	10 (32.3)	13 (41.9)	5 (16.1)	17 (54.8)	9 (29)
	19	6 (31.6)	4 (21.1)	9 (47.4)	11 (57.9)	8 (42.1)	4 (21.1)	8 (42.1)	7 (36.8)	5 (26.3)	10 (52.6)	4 (21.1)
Stagea
1 + 2	24	8 (33.3)	15 (62.5)	9(4.2)	7 (29.2)	17 (70.8)	5 (20.8)	4 (16.7)	15 (62.5)	7 (29.2)	9 (37.5)	8 (33.3)
3 + 4	26	4 (15.4)	1(11.6)	19(73)	19 (73.1)	7 (26.9)	7 (26.9)	14 (53.8)	5 (19.1)	3 (11.5)	18 (69.2)	5 (19.2)
Distant metastasis
Absent	26	7 (26.9)	8 (30.8)	11 (42.3)	11 (42.3)	15 (57.7)	7 (26.9)	7 (26.9)	12 (46.2)	4 (15.4)	16 (61.5)	6 (23.1)
Present	24	12(20.8)	8 (33.3)	11 (45.8)	15 (62.5)	9 ( 37.5)	5 (20.8)	11 (45.8)	8 (33.3)	6 (25)	11 (45.8)	7 (39.2)
Survival (mo)a
60.62 ± 26.68 ≥	26	11 (42.3)	0	15 (57.7)	22 (84.6)	4 (15.4)	7 (26.9)	15 (57.6)	4 (42.4)	4 (15.5)	21 (80.7)	1 (3.8)
60.62 ± 26.68 <	24	1 (4.2 )	16 (66.6 )	7 (29.2)	4 (16.7)	20 (83.3)	5 (20.8)	3 (12.5)	16 (87.5)	6 (25)	6 (25)	12 (50)

^aP < 0.05. Downregulation of Notch and upregulation of Numb, Itch, and Siah-1 are associated with better prognosis. (↑): Upregulation, (↓): Downregulation; WD: Well-differentiated; MD: Moderately differentiated; PD: Poorly differentiated; LNM: Lymph node metastasis.